Collegium Pharmaceutical (COLL) vs Harrow (HROW)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Harrow (HROW) has outperformed Collegium Pharmaceutical (COLL) over the past year, losing 26.9% versus a loss of 34.3%. Over five years, HROW leads with a +209.6% price change compared with +4.5% for COLL. Harrow is the larger company by market cap ($1.15 billion vs $719.0 million), about 1.6 times the size.
On valuation, Collegium Pharmaceutical trades at a lower forward P/E (3.3x vs 11.1x for Harrow).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | COLL | HROW |
|---|---|---|
| Share price | $22.09 | $30.67 |
| Market cap | $718.99M | $1.15B |
| 1-day change | +0.71% | +0.16% |
| YTD return | -52.63% | -37.51% |
| 1-year return | -34.32% | -26.92% |
| 5-year return | +4.53% | +209.61% |
| P/E ratio (TTM) | 17.39 | — |
| Forward P/E | 3.32 | 11.06 |
| EPS (TTM) | $1.27 | $-0.99 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $50.79 | $54.85 |
| 52-week low | $21.43 | $28.54 |
| Distance from 52-week high | -56.51% | -44.08% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +121.87% | +111.93% |
| Average volume | 748.29K | 555.14K |
| Shares outstanding | 32.56M | 37.49M |
| Employees | 423 | 373 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Collegium Pharmaceutical
COLL stock →Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.
Health Care · Biotechnology: Pharmaceutical Preparations · 423 employees
About Harrow
HROW stock →Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. It operates through Branded and ImprimisRx segments.
Health Care · Biotechnology: Pharmaceutical Preparations · 373 employees
COLL vs HROW FAQ
Which is bigger, Collegium Pharmaceutical or Harrow?
Harrow (HROW) is larger, with a market capitalization of $1.15B compared with $718.99M for Collegium Pharmaceutical (COLL).
Which stock has performed better over the past year, COLL or HROW?
HROW returned -26.92% over the past 12 months, compared with -34.32% for COLL (price return, excluding dividends). Past performance does not predict future results.
Are Collegium Pharmaceutical and Harrow in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.